NYSE:BDX - Becton Dickinson and Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$247.03 +0.05 (+0.02 %)
(As of 07/23/2018 09:21 AM ET)
Previous Close$246.98
Today's Range$246.01 - $248.35
52-Week Range$191.53 - $248.57
Volume714,820 shs
Average Volume905,170 shs
Market Capitalization$66.01 billion
P/E Ratio26.06
Dividend Yield1.21%
Becton Dickinson and logoBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Receive BDX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment


Debt-to-Equity Ratio1.07
Current Ratio1.70
Quick Ratio1.12


Trailing P/E Ratio26.06
Forward P/E Ratio22.48
P/E Growth1.72

Sales & Book Value

Annual Sales$12.09 billion
Price / Sales5.46
Cash Flow$14.0999 per share
Price / Cash17.52
Book Value$56.89 per share
Price / Book4.34


EPS (Most Recent Fiscal Year)$9.48
Net Income$1.10 billion
Net Margins-0.46%
Return on Equity14.27%
Return on Assets5.24%


Outstanding Shares267,200,000
Market Cap$66,006.87

Becton Dickinson and (NYSE:BDX) Frequently Asked Questions

What is Becton Dickinson and's stock symbol?

Becton Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

How often does Becton Dickinson and pay dividends? What is the dividend yield for Becton Dickinson and?

Becton Dickinson and announced a quarterly dividend on Monday, April 23rd. Shareholders of record on Friday, June 8th will be paid a dividend of $0.75 per share on Friday, June 29th. This represents a $3.00 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date of this dividend is Thursday, June 7th. View Becton Dickinson and's Dividend History.

How were Becton Dickinson and's earnings last quarter?

Becton Dickinson and Co (NYSE:BDX) announced its quarterly earnings results on Thursday, May, 3rd. The medical instruments supplier reported $2.65 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.63 by $0.02. The medical instruments supplier earned $4.22 billion during the quarter, compared to the consensus estimate of $4.12 billion. Becton Dickinson and had a negative net margin of 0.46% and a positive return on equity of 14.27%. The company's revenue for the quarter was up 42.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.30 EPS. View Becton Dickinson and's Earnings History.

When is Becton Dickinson and's next earnings date?

Becton Dickinson and is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Becton Dickinson and.

What guidance has Becton Dickinson and issued on next quarter's earnings?

Becton Dickinson and issued an update on its FY18 earnings guidance on Thursday, May, 3rd. The company provided EPS guidance of $10.90-$11.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.96. The company issued revenue guidance of $15.84-$15.90, compared to the consensus revenue estimate of $15.85 billion.

What price target have analysts set for BDX?

15 analysts have issued 12 month price objectives for Becton Dickinson and's stock. Their forecasts range from $175.00 to $260.00. On average, they expect Becton Dickinson and's share price to reach $239.6667 in the next twelve months. This suggests that the stock has a possible downside of 3.0%. View Analyst Ratings for Becton Dickinson and.

What is the consensus analysts' recommendation for Becton Dickinson and?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton Dickinson and in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Becton Dickinson and's key competitors?

Who are Becton Dickinson and's key executives?

Becton Dickinson and's management team includes the folowing people:
  • Mr. Vincent A. Forlenza, Chairman & CEO (Age 65)
  • Mr. Thomas E. Polen Jr., Pres (Age 45)
  • Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 61)
  • Mr. Alexandre Conroy, Pres of Worldwide Medication & Procedural Solutions (Age 55)
  • Mr. James W. Borzi, Exec. VP of Global Operations & Chief Supply Chain Officer (Age 55)

Has Becton Dickinson and been receiving favorable news coverage?

Media stories about BDX stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Becton Dickinson and earned a coverage optimism score of 0.22 on Accern's scale. They also assigned headlines about the medical instruments supplier an impact score of 46.22 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Becton Dickinson and's major shareholders?

Becton Dickinson and's stock is owned by many different of retail and institutional investors. Top institutional investors include Jensen Investment Management Inc. (0.73%), Bank of Montreal Can (0.27%), Atalanta Sosnoff Capital LLC (0.10%), Rathbone Brothers plc (0.08%), Cornerstone Wealth Management LLC (0.07%) and Westpac Banking Corp (0.07%). Company insiders that own Becton Dickinson and stock include Alexandre Conroy, David F Melcher, Ellen R Strahlman, Gary M Cohen, James W Borzi, Jeffrey S Sherman, John E Gallagher, Linda M Tharby, Nabil Shabshab, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr and Timothy M Ring. View Institutional Ownership Trends for Becton Dickinson and.

Which institutional investors are selling Becton Dickinson and stock?

BDX stock was sold by a variety of institutional investors in the last quarter, including Jensen Investment Management Inc., NN Investment Partners Holdings N.V., Bank of Montreal Can, Hartford Investment Management Co., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Hardman Johnston Global Advisors LLC, Sit Investment Associates Inc. and Nippon Life Global Investors Americas Inc.. Company insiders that have sold Becton Dickinson and company stock in the last year include Alexandre Conroy, Ellen R Strahlman, Gary M Cohen, James W Borzi, John E Gallagher, Linda M Tharby, Nabil Shabshab, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr and Timothy M Ring. View Insider Buying and Selling for Becton Dickinson and.

Which institutional investors are buying Becton Dickinson and stock?

BDX stock was purchased by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, Assenagon Asset Management S.A., James Hambro & Partners, Westpac Banking Corp, Rathbone Brothers plc, Addenda Capital Inc., Addenda Capital Inc. and Bath Savings Trust Co. View Insider Buying and Selling for Becton Dickinson and.

How do I buy shares of Becton Dickinson and?

Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Becton Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $247.03.

How big of a company is Becton Dickinson and?

Becton Dickinson and has a market capitalization of $66.01 billion and generates $12.09 billion in revenue each year. The medical instruments supplier earns $1.10 billion in net income (profit) each year or $9.48 on an earnings per share basis. Becton Dickinson and employs 41,933 workers across the globe.

How can I contact Becton Dickinson and?

Becton Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.

MarketBeat Community Rating for Becton Dickinson and (NYSE BDX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  371 (Vote Outperform)
Underperform Votes:  460 (Vote Underperform)
Total Votes:  831
MarketBeat's community ratings are surveys of what our community members think about Becton Dickinson and and other stocks. Vote "Outperform" if you believe BDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.